

Message

From: psmatthancock [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=8DDDC7F87798480280E3A7AA57CB8D62-PSMATTHANCO]
Sent: 17/03/2020 22:30:29
To: Sharon Peacock [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=4b25d70f692447469261ae948c92dcd3-Sharon Peac]; MEDICALDIRECTOR2, England (NHS ENGLAND & NHS IMPROVEMENT - X24) [england.medicaldirector2@nhs.net]; Oldfield, Steve [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e53f3b0e01c74d5ba7c94c7cd14c524b-SOLDfield]; Hadley Beeman [hadley.beeman@nhsx.nhs.uk]; Kristen McLeod [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9ec3823a6ea9440b9e044d6a88d08ca9-Kristen McL]; PsBethell [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6f0a1735f9834b5ca9c02d2016d42e9f-PsBethell]; June Raine [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=5d4ac687ee354c9cac76d09f23ee6ade-June Raine]; Whitty, Chris [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0b3ee62e0ca04e978730b14f9b416a1e-Whitty, Chr]; **NR** [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d21258c9254e4e32942f15c21ee78f6f-**NR**]; Government Chief Scientific Adviser (GO-Science) [GCSA@**I&S**]; Duncan Selbie [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=402d500ef6d3426b81ab39cfd0f5bcf5-Duncan Selb]; **NR** @phe.gov.uk]; William Warr [WWarr@no10.gov.uk]; Malcolm Reid [MReid@no10.gov.uk]; Imran Shafi [IShafi@no10.gov.uk]; Simon Eccles [simon.eccles@nhsx.nhs.uk]; Fowler, Aidan [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b1153bf5f6d34a1dab23cf34073eaa9e-AFowler5]
CC: Permanent Secretary [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c95fac41d7c24f8ba5faa2072856bcd-f-Permanent S]; PsBethell [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6f0a1735f9834b5ca9c02d2016d42e9f-PsBethell]; **NR** @nhsx.nhs.uk]; **NR** [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d93ca8c4416b4aa2ac18528d0ee80c18-**NR**]; Senior Copylist [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=45360eff9fa2467d8fead1fe51e67238-NEWSeniorCo]
Subject: Brief readout from no10 mass testing roundtable

All,

In the interests of time I'm only to send round the four key actions from the mass testing roundtable in no10 this evening. Please do shout if you think I've misrepresented any of the points, and note that for now I haven't shared this with industry.

1. **Sharon** and team are looking at the best kitemarked products on the market for testing those who have had the condition and will have a list tomorrow of those appropriate. She will then work with **Steve Oldfield** to purchase. The first call is for key workers in the NHS to have access to the testing to help people return to work. **Sharon** and **Steve Powis** to work out a plan for this.
2. **Jeremy Farrar** to lead on the research point, looking at a serology based survey across the population, with input from **Sharon** as necessary.
3. **Hadley** to talk to **NR** and **NR** about mass serology testing through at home kits, ensuring that it links back into the NHS through the work NHSX is leading on.
4. **Lord Bethell**, **Jeremy Farrar** and **Kristen** to come up with a plan for the fastest way to scale up antigen testing (the "do you have it now" test) using entirely non NHS/PHE facilities, starting with Thermofisher possible capacity.

Other key points

- i. Sharon is leading on the work around 'do you have it now' testing.

- ii. June has said the MHRA will publish performance specs to allow companies to get involved as fast as possible.
- iii. CMO has said it's important for the most accurate tests (as it will take time to develop accuracy) to be used on NHS staff and those who are vulnerable.
- iv. Companies had concerns about shortages of products for the process e.g. swabs and reagents.
- v. **Duncan** to look at how swabs are being used across the system
- vi. **NR** said Universities can explore how their capacity can be used.

Many thanks

NR



Department
of Health &
Social Care

NR

Private Secretary to Secretary of State for Health and Social Care
9th Floor, 39 Victoria Street, SW1H 0EU

E: **NR** [@dhsc.gov.uk](mailto:NR@dhsc.gov.uk) T: **I&S**

DHSC recipients please note: this email will not be saved by Private Office. If you need it for audit purposes, please keep a copy for your records.

This e-mail and any attachments is intended only for the attention of the addressee(s). Its unauthorised use, disclosure, storage or copying is not permitted. If you are not the intended recipient, please destroy all copies and inform the sender by return e-mail. Any views expressed in this message are not necessarily those of the Department of Health and Social Care. Please note: Incoming and outgoing email messages are routinely monitored for compliance with our policy on the use of electronic communications.